Novartis Ag (NVS) Cash from Operations (2009 - 2025)
Novartis Ag recorded quarterly Cash from Operations of 6664000000.0 in Q2 2025, down 6.67% quarter-over-quarter from 7140000000.0 in Q4 2024, and up 36.7% year-over-year from 4875000000.0 in Q2 2024.
Novartis Ag's Cash from Operations history runs 11 years deep, the most recent figure standing at 6664000000.0 for Q2 2025.
- In Q2 2025, Cash from Operations rose 36.7% year-over-year to 6664000000.0; the TTM figure through Jun 2025 stood at 25212000000.0 (up 23.66% YoY), while the FY2025 annual figure was 19144000000.0, up 8.66% from the prior year.
- Cash from Operations came in at 6664000000.0 for Q2 2025 at Novartis Ag, down from 7140000000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 7140000000.0 in Q4 2024 to a low of 3576000000.0 in Q2 2023.
- A 5-year average of 5371222222.22 and a median of 5404000000.0 in 2022 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations retreated 13.7% in 2022 and surged 36.7% in 2025, its largest moves.
- Novartis Ag's Cash from Operations stood at 6262000000.0 in 2021, then decreased by 13.7% to 5404000000.0 in 2022, then rose by 20.89% to 6533000000.0 in 2023, then grew by 9.29% to 7140000000.0 in 2024, then decreased by 6.67% to 6664000000.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 6664000000.0, 7140000000.0, and 4875000000.0 for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.33 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.51 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.83 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.10 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 6.66 Bn |
| Jun 30, 2025 | 6.66 Bn |
| Dec 31, 2024 | 7.14 Bn |
| Dec 31, 2024 | 7.14 Bn |
| Jun 30, 2024 | 4.88 Bn |
| Jun 30, 2024 | 4.88 Bn |
| Dec 31, 2023 | 6.53 Bn |
| Dec 31, 2023 | 6.53 Bn |
| Jun 30, 2023 | 3.58 Bn |
| Jun 30, 2023 | 3.58 Bn |
| Dec 31, 2022 | 5.40 Bn |
| Dec 31, 2022 | 5.40 Bn |
| Jun 30, 2022 | 3.76 Bn |
| Jun 30, 2022 | 3.76 Bn |
| Dec 31, 2021 | 6.26 Bn |
| Dec 31, 2021 | 6.26 Bn |
| Jun 30, 2021 | 4.13 Bn |
| Jun 30, 2021 | 4.13 Bn |
| Dec 31, 2020 | 6.49 Bn |
| Dec 31, 2020 | 6.49 Bn |
| Jun 30, 2020 | 3.96 Bn |
| Jun 30, 2020 | 3.96 Bn |
| Jun 30, 2019 | 3.11 Bn |
| Jun 30, 2019 | 3.11 Bn |
| Jun 30, 2018 | 3.94 Bn |
| Jun 30, 2018 | 3.94 Bn |
| Jun 30, 2017 | 3.58 Bn |
| Jun 30, 2017 | 3.58 Bn |
| Mar 31, 2010 | 3,307.00 |
| Mar 31, 2010 | 3,307.00 |
| Dec 31, 2009 | 12.19 Bn |
| Dec 31, 2009 | 12.19 Bn |
| Sep 30, 2009 | 3,154.00 |
| Sep 30, 2009 | 3,154.00 |
| Jun 30, 2009 | 2,618.00 |
| Jun 30, 2009 | 2,618.00 |
| Mar 31, 2009 | 1,953.00 |
| Mar 31, 2009 | 1,953.00 |